Sign in to fuzzto save your conversations, follow your research and come back anytime.
Senores Pharmaceuticals
SENORES
NSE
BSE
NSEBSESectorHealthcare
1,430.40
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Senores Pharmaceuticals drives strong revenue and margin growth across regulated and emerging markets, supported by rapid IPO fund deployment and pipeline expansion.
Consolidated revenue grows from ₹138 Cr to ₹180.2 Cr from Q1 FY26 to Q1 FY27, driven by consistent market demand.
Branded generics revenue declines from ₹8.2 Cr to ₹8.0 Cr from Q1 FY26 to Q1 FY27, signaling demand softening.
Regulated markets EBITDA margin improves from 35.5% to 40% from Q1 FY26 to Q1 FY27, maintaining stable profitability.
Consolidated finance cost rises from ₹5.0 Cr to ₹7.2 Cr from Q1 FY26 to Q1 FY27, indicating higher debt servicing obligations.
Emerging markets approved products expand from 308 to 513 from Q1 FY26 to Q1 FY27, strengthening the commercial pipeline.
Consolidated other expenses climb from ₹20.8 Cr to ₹30.8 Cr from Q1 FY26 to Q1 FY27, signaling rising operational overheads.
Consolidated EBITDA margin rises from 24.8% to 29.8% from Q1 FY26 to Q1 FY27, reflecting sustained pricing power.
Consolidated employee cost increases from ₹21.7 Cr to ₹29.9 Cr from Q1 FY26 to Q1 FY27, reflecting hiring for capacity expansion.
IPO funds utilized increase from ₹241 Cr to ₹399.5 Cr from Q1 FY26 to Q1 FY27, confirming steady project execution.
Others (API sales) revenue shifts from ₹3.0 Cr to ₹6.8 Cr from Q1 FY26 to Q1 FY27, indicating volatile API demand.
